Odyssey Therapeutics is a clinical-stage biotechnology company that recently transitioned to a public entity following its IPO. The company reported 48,067,877 shares of common stock outstanding as of November 2, 2026, and continues to incur substantial net losses as it advances its lead product candidates, OD-001 and OD-002, through clinical and preclinical development.
Odyssey Therapeutics reported third quarter 2026 financial results, ending the period with $387 million in cash and equivalents. The company highlighted clinical progress for its RIPK2 inhibitor OD-001 in ulcerative colitis and the completion of IND-enabling studies for its SLC15A4 inhibitor OD-002.
Term
Q3 2026
“Over the past several months, we have made meaningful progress across our entire pipeline, highlighted by additional analyses from the Phase 2a induction period for OD-001 demonstrating that clinical efficacy is supported by concordant biomarker and transcriptomic findings, further reinforcing previously established clinical proof of concept in patients with ulcerative colitis.”
Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics
“We have also continued to advance the clinical development of OD-001 while completing IND-enabling studies for OD-002, our SLC15A4 inhibitor. Together with an enhanced executive leadership team and strong financial foundation, these achievements position us to execute on our clinical development strategy and drive continued progress throughout our portfolio.”
Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics
Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.